EDAP TMS SA -ADR
FOCLNASDAQTrading Snapshot
- Day Range
- $346.61 – $357.20
- 52-Week Range
- —
- Volume
- $4.98B
- Avg Volume
- $3.89B
- Shares Outstanding
- —
- Next Earnings
- Oct 26, 2026
Fundamentals Snapshot
- Annual Revenue
- $35.49B
- Last Q Revenue
- $8.54B
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
Why Investors Own FOCL
- ✓High-growth profile — revenue up +58.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 31% gross margin and 7% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About EDAP TMS SA -ADR
A company profile for EDAP TMS SA -ADR isn’t available yet — check back soon.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Dermata Therapeutics (NASDAQ:DRMA) stock moved upwards by 44.4% to $1.56 during Tuesday's after-market session. The company's market cap stands at $4.5 million. As per the news, the Q2 earnings report
FocalTherics Reports Preliminary Q2 Sales Of $12.7M-$13.2M, Up 34%-39% Year-On-Year
During the second quarter of 2026, the Extracorporeal Shock Wave Lithotripsy (ESWL) and Distribution segments met the criteria to be classified as held for sale under ASC 205-20, Presentation of Financial Statements —
FocalTherics Announces Underwritten Public Offering Of ADSs
The Company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the ADSs sold in the Offering on the same terms and conditions. The terms of the ADSs to be issued in the Offering are